MicroAlgo (NASDAQ:MLGO) Bolsa

MicroAlgo

MicroAlgo Inc is divided into two segments: Central processing algorithm services & Intelligent chips and services. The majority is from the Central Processing Algorithm Services. which refers to a range of computing algorithms, analytical algorithms, recommendation algorithms, & acceleration algorithms. The businesses engaged in internet advertisement, game development, intelligent chip design, finance, retail, & logistics depend on the ability to process & analyze data with optimized computing software & hardware capable of handling the data workload. Intelligent chips and services revenues include revenues generated from the resale of intelligent chips. All of the Company's net revenues were generated in the PRC, Hong Kong, & Singapore, out of which the majority is from the PRC.

Mercados

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ATNF

BDRX

DECK

HNRG

IMMX

INEO

INTU

LITM

LTBR

MLGO

MNSO

OKLO

ROST

SGBX

SOBR

VTAK

Intuit sorprende al mercado con ingresos y BPA mejores de lo esperado. Revisa los mayores ganadores y perdedores del premercado.

Las acciones de Intuit (INTU) cotizan un 8% más alto; Aquí están 20 acciones que se mueven en el premercado

Tesla, Luminar, Reddit, Intel, Alibaba: Why These 5 Stocks Are On Investors' Radars Today

Equities

PLTR

TSLA

Wall Street revive con fuertes alzas en acciones tecnológicas y sorpresivos movimientos que sacuden al mercado financiero.

Microalgo, Palantir, 23Andme, AMD y Tesla: 5 acciones que están en el radar de los inversores

EVAX

IDAI

INTZ

LIDR

LKCO

LUXH

MGIH

MRBK

MTRX

NEUP

ONDS

QRHC

RVSN

SLDP

VIRX

WTBA

Descubre las acciones que lideran los movimientos en la apertura del mercado, incluyendo repuntes destacados y caídas sorprendentes.

Acciones de Evaxion Biotech (EVAX) suben alrededor del 62%; 20 acciones que se mueven en el premercado

MicroAlgo Inc

Offerings

KANZHUN LIMITED Announces Pricing Of 34,500,000 Class A Ordinary Share Offer At HK$66.00 Per Share

HII And C3 AI Partner To Expand Digital Technologies, Apply AI To Accelerate Shipbuilding Throughput At HII's Newport News Shipbuilding And Ingalls Shipbuilding Divisions

Media

CURI

Curiosity University Launches On Amazon Prime Video Channels in Sweden

Asset Sales

ROCK

Gibraltar Industries Board approves Plan To Sell Renewables Business

Management

GAIA

Gaia Appoints Kiersten Medvedich As CEO

Rumble Added To Russell 2000 And Russell 3000 Indexes

Cantor Fitzgerald analyst Jonathan Ruykhaver initiates coverage on SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) with a Overweight rating and announces Price Target of $29.

Price Target

Initiation

Analyst Ratings

SAIL

Cantor Fitzgerald Initiates Coverage On SailPoint with Overweight Rating, Announces Price Target of $29

Maxim Group analyst Anthony Vendetti initiates coverage on Laird Superfood (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LSF#AMEX">LSF</a>) with a Buy rating and announces Price Target of $12.

Maxim Group Initiates Coverage On Laird Superfood with Buy Rating, Announces Price Target of $12

At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone
Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>, HKEX: 9688))) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis.
Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS as compared to placebo plus chemotherapy in people living with unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer with FGFR2b overexpression and who are non-HER2 positive. FGFR2b overexpression was defined as 2+/3+ staining in ≥10% of tumor cells by centrally performed immunohistochemistry (IHC) testing.
A Phase 3 study of bemarituzumab plus chemotherapy and nivolumab is also ongoing in patients with first-line gastric cancer, with data readout anticipated in H2 2025.

ZLAB

Zai Lab Says Phase 3 FORTITUDE-101 Clinical Trial Evaluating First-Line Bemarituzumab Plus Chemotherapy Meets Primary Endpoint Of Overall Survival At Pre-Specified Interim Analysis

JMP Securities analyst Andrew Boone maintains Grindr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>) with a Market Outperform and raises the price target from $24 to $27.

GRND

JMP Securities Maintains Market Outperform on Grindr, Raises Price Target to $27

Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) reported quarterly losses of $(0.36) per share. This is a 14.29 percent increase over losses of $(0.42) per share from the same period last year.

Earnings

Regencell Bioscience H1 EPS $(0.36) Up From $(0.42) YoY

High-Trend International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>), a Nasdaq-listed global shipping and logistics company, proudly acknowledges the recent correspondence from President Donald J. Trump in response to a letter submitted by Mr. Brian B. Su, the Company's Independent Director and Chairman of the Compensation Committee. In his letter dated June 18, 2025, President Trump expressed appreciation for Mr. Su's views on restoring American strength on the world stage and reaffirmed his administration's commitment to revitalizing American leadership, defense readiness, and strategic dominance in global affairs.

HTCO

High-Trend International Acknowledges President Trump Letter To Board Chairman On Company Affairs

Contracts

BZAI

Blaize Holdings Announces Its AI Platform Will Be Deployed Across Intelligence Surveillance Endpoints; Total Value Of Contracted Purchase Order ~$56M

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">252.8400</td>
<td align="right">2.070</td>
<td align="right">0.82</td>
<td>75.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">108.5600</td>
<td align="right">0.880</td>
<td align="right">0.81</td>
<td>8.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">52.1850</td>
<td align="right">0.245</td>
<td align="right">0.47</td>
<td>330.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">41.2400</td>
<td align="right">0.120</td>
<td align="right">0.29</td>
<td>3.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">88.0600</td>
<td align="right">0.170</td>
<td align="right">0.19</td>
<td>421</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">134.0100</td>
<td align="right">0.080</td>
<td align="right">0.05</td>
<td>8.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">146.8601</td>
<td align="right">0.070</td>
<td align="right">0.04</td>
<td>5.2K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">80.80</td>
<td align="right">-0.53</td>
<td align="right">-0.66</td>
<td>67.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">80.46</td>
<td align="right">-0.09</td>
<td align="right">-0.12</td>
<td>1.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">85.22</td>
<td align="right">-0.08</td>
<td align="right">-0.10</td>
<td>31.3K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

ETFs

XLRE

Leading And Lagging Sectors For June 30, 2025

Thomas (Tom) Lee, the Founder of Fundstrat and CIO of Fundstrat Capital, will become Chairman of the Board of Directors effective today.
The transaction was led by MOZAYYX with participation from Founders Fund, Pantera, FalconX, Republic Digital, Kraken, Galaxy Digital, DCG, Diametric Capital, Occam Crest Management, and Thomas Lee.
Upon the closing of the Private Placement, BitMine will advance its treasury strategy on Ethereum.
BitMine Immersion continues to enhance its asset-light and mining business by increasing its existing treasury holdings by over 16x.
LAS VEGAS, June 30, 2025 /PRNewswire/ -- (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#NYSE">BMNR</a>) ("BitMine" or the "Company") today announced the pricing and signing of a private placement for the purchase and sale of 55,555,556 shares of common stock (or common stock equivalents in lieu thereof) at a price of $4.50 per share for expected aggregate gross proceeds of approximately $250 million before deducting placement agent fees and other offering expenses (funded in a combination of cash and cryptocurrencies) to implement an Ethereum treasury strategy.
The transaction was led by MOZAYYX with participation from a high quality group of investors including Founders Fund, Pantera, FalconX, Republic Digital, Kraken, Galaxy Digital, DCG, Diametric Capital, Occam Crest Management, and Thomas Lee.
The closing of the offering is expected to occur on or about July 3, 2025, subject to the satisfaction of customary closing conditions, including without limitation, the authorization of the Supplemental Listing Application by the NYSE American. The Company intends to use the net proceeds of the offering to acquire the native cryptocurrency of Ethereum blockchain commonly referred to as "ETH" and contribute the ETH to the Company's treasury operations. ETH will serve as the Company's primary treasury reserve asset.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

BMNR

BitMine Announces $250M Private Placement Of 55.56M Shares Of Common Stock At $4.50/Share To Launch Ethereum Treasury Strategy; Tom Lee Named Chairman

JMP Securities analyst Jordan Bender maintains Genius Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) with a Market Outperform and raises the price target from $12 to $13.

GENI

JMP Securities Maintains Market Outperform on Genius Sports, Raises Price Target to $13

Acuren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIC#NYSE">TIC</a>) (the "Company" or "Acuren"), a leading provider of critical asset integrity services, today announced that its registration statement on Form S-4 (the "Registration Statement") filed with Securities and Exchange Commission (the "SEC") in connection with the proposed merger between the Company and NV5 Global, Inc. (("NV5", NASDAQ:<a href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>), was declared effective by the SEC on June 27, 2025. Notice of Acuren's meeting of stockholders to be held in connection with the proposed merger and a definitive joint proxy statement/prospectus is expected to be mailed on or about July 1, 2025, to stockholders of record of the Company as of June 30, 2025. BEFORE MAKING ANY VOTING DECISION, THE COMPANY'S STOCKHOLDERS ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING, WHEN AVAILABLE, THE JOINT PROXY STATEMENT/PROSPECTUS, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER.&nbsp;

NVEE

Acuren Announces SEC Approval Of Registration Statement For Proposed Merger With NV5 Global

Future Fintech Group Inc. (NASDAQ:&nbsp;<a href="https://www.ftft.com/en/">FTFT</a>), (hereinafter referred to as "Future FinTech", "FTFT" or the "Company"),&nbsp;a comprehensive financial and digital technology service provider, today announced certain changes to its management and Board of Directors.
On June 20, 2025, Mr. Ming Yi resigned from his position as the Chief Financial Officer of the Company, Mr. Fuyou Li resigned from his position as the Chairman of the Board and as a member of the Board's audit and compensation committees, and Ms. Ying Li resigned from her positions as a director of the Board and the Vice President of the Company. The resignations of Mr. Ming Yi, Mr. Fuyou Li and Ms. Ying Li from these positions were not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company. To fill these vacancies, on June 26, 2025, the Company's Board of Directors appointed Ms. Ting (Alina) Ouyang as a director of the Board and the Chief Financial Officer of the Company, and Mr. David Xu as the Chairman of the Board and as a member of the Board's audit and compensation committees of the Company.

FTFT

Future Fintech Appoints Ting Ouyang As CFO And David Xu As Chairman Of The Board

KYTX

Kyverna Therapeutics Appoints Marc Grasso, M.D. As CFO, Effective Today

JMP Securities analyst Roy Buchanan maintains Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Market Outperform and maintains $59 price target.

CDTX

JMP Securities Maintains Market Outperform on Cidara Therapeutics, Maintains $59 Price Target

Press Releases

MicroAlgo Inc. Develops Quantum Image Encryption Algorithm Based on Quantum Key Images, Offering A Higher Security Image Protection Solution

MicroAlgo Inc. Develops Quantum Convolutional Neural Network (QCNN) Architecture to Enhance the Performance of Traditional Computer Vision Tasks Using Quantum Mechanics Principles

MicroAlgo Inc. Develops Blockchain-Based Traceable IP Rights Protection Algorithm

MicroAlgo Inc. Announces Research on Quantum Information Recursive Optimization (QIRO) Algorithm, for Combinatorial Optimization Problems to Expand and Solve New Ideas

MicroAlgo Inc. Announces a Quantum Entanglement-Based Novel Training Algorithm — Entanglement-Assisted Training Algorithm for Supervised Quantum Classifiers

MicroAlgo Inc. Researches Quantum Machine Learning Algorithms to Accelerate Machine Learning Tasks

Navitas (NASDAQ: NVTS) Surges on NVIDIA Deal – SNYR, VIGL, XAGE Lead $2 Stock Watch Now, More Inside

MicroAlgo Inc. Explores Optimization of Quantum Error Correction Algorithms to Enhance Quantum Algorithm Accuracy

MicroAlgo Inc. Adopts Quantum Phase Estimation (QPE) Method to Enhance Quantum Neural Network Training

MicroAlgo Inc. Integrates Quantum Image LSQb Algorithm with Quantum Encryption Technology to Build a More Secure Quantum Information Hiding and Transmission System

Comments

MicroAlgo

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL